The Real Price of GLP-1 Drugs
Same molecule. 96× price spread. Here's what patients actually pay in April 2026.
Free to embed. Please link back.
This infographic is released under a Creative Commons BY 4.0 license — you can republish, adapt, and share it on your blog, newsletter, or social feed. The only condition is attribution with a link back to this page so readers can find the latest version.
Paste this HTML into your blog, Substack, or site. The infographic will link back to the source.
What this shows
The US GLP-1 market has fragmented into at least eight distinct pricing channels for the same underlying molecule. Semaglutide — the active ingredient in Ozempic and Wegovy — can cost as little as $14/month as an Indian generic (post-patent expiry, March 2026), or as much as $1,349/month at US wholesale acquisition cost. That's a 96× spread before any discount, rebate, or savings card is applied.
For patients with commercial insurance and a manufacturer savings card, the copay is $25/month regardless of whether they choose Ozempic, Wegovy, Mounjaro, Zepbound, or Foundayo. For Medicare patients, TrumpRx brings effective costs to $50/month. The gap opens up for uninsured patients: LillyDirect starter doses of Foundayo or Wegovy Pill land at $149/month, while self-pay injectable Wegovy through NovoCare runs $499/month.
Novo Nordisk has announced a ~35–50% WAC cut to $675/month effective January 2027, which will finally move the sticker price closer to what patients actually pay. Until then, the gap between list price and real price remains the single most confusing feature of the GLP-1 market.